Amicus Therapeutics Inc (FOLD)
10.09
-0.28
(-2.70%)
USD |
NASDAQ |
Nov 14, 16:00
10.10
+0.02
(+0.15%)
After-Hours: 20:00
Amicus Therapeutics Net Income (TTM): -104.69M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | -104.69M |
| June 30, 2024 | -119.54M |
| March 31, 2024 | -147.07M |
| December 31, 2023 | -151.58M |
| September 30, 2023 | -173.61M |
| June 30, 2023 | -185.32M |
| March 31, 2023 | -204.24M |
| December 31, 2022 | -236.57M |
| September 30, 2022 | -263.98M |
| June 30, 2022 | -280.99M |
| March 31, 2022 | -270.06M |
| December 31, 2021 | -250.46M |
| September 30, 2021 | -238.58M |
| June 30, 2021 | -252.30M |
| March 31, 2021 | -253.57M |
| December 31, 2020 | -276.85M |
| September 30, 2020 | -295.18M |
| June 30, 2020 | -292.98M |
| March 31, 2020 | -325.04M |
| December 31, 2019 | -356.39M |
| September 30, 2019 | -344.74M |
| June 30, 2019 | -442.09M |
| March 31, 2019 | -419.38M |
| December 31, 2018 | -348.99M |
| September 30, 2018 | -340.12M |
| Date | Value |
|---|---|
| June 30, 2018 | -292.62M |
| March 31, 2018 | -278.93M |
| December 31, 2017 | -284.00M |
| September 30, 2017 | -273.44M |
| June 30, 2017 | -208.43M |
| March 31, 2017 | -211.34M |
| December 31, 2016 | -200.04M |
| September 30, 2016 | -184.29M |
| June 30, 2016 | -175.44M |
| March 31, 2016 | -151.52M |
| December 31, 2015 | -132.12M |
| September 30, 2015 | -110.44M |
| June 30, 2015 | -89.79M |
| March 31, 2015 | -77.27M |
| December 31, 2014 | -68.93M |
| September 30, 2014 | -59.94M |
| June 30, 2014 | -57.38M |
| March 31, 2014 | -58.12M |
| December 31, 2013 | -59.63M |
| September 30, 2013 | -57.41M |
| June 30, 2013 | -59.11M |
| March 31, 2013 | -53.11M |
| December 31, 2012 | -48.78M |
| September 30, 2012 | -47.43M |
| June 30, 2012 | -40.90M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-356.39M
Minimum
Dec 2019
-104.69M
Maximum
Sep 2024
-233.95M
Average
-251.38M
Median
Net Income (TTM) Benchmarks
| Tonix Pharmaceuticals Holding Corp | -149.01M |
| Alnylam Pharmaceuticals Inc | -332.26M |
| Ionis Pharmaceuticals Inc | -358.81M |
| Arbutus Biopharma Corp | -76.70M |
| Krystal Biotech Inc | 52.37M |